These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25940025)

  • 1. Drug transport and metabolism of novel anticancer drugs.
    Peters GJ; Honeywell RJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):661-3. PubMed ID: 25940025
    [No Abstract]   [Full Text] [Related]  

  • 2. A new probe for targeting drug delivery system.
    Yu Z; Wang B; Sui J; Feng Y; Zheng C
    Med Hypotheses; 2009 Jan; 72(1):43-4. PubMed ID: 18829175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of herbal products on the metabolism and transport of anticancer agents.
    He SM; Yang AK; Li XT; Du YM; Zhou SF
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1195-213. PubMed ID: 20701553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and related anticancer drugs: recent advances and insights.
    Barnes KR; Lippard SJ
    Met Ions Biol Syst; 2004; 42():143-77. PubMed ID: 15206102
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral delivery of anticancer drugs III: formulation using drug delivery systems.
    Mazzaferro S; Bouchemal K; Ponchel G
    Drug Discov Today; 2013 Jan; 18(1-2):99-104. PubMed ID: 22981667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral delivery of anticancer drugs II: the prodrug strategy.
    Mazzaferro S; Bouchemal K; Ponchel G
    Drug Discov Today; 2013 Jan; 18(1-2):93-8. PubMed ID: 22960308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential successes and challenges of targeted anticancer therapies.
    Keefe D; Stringer A
    Curr Opin Support Palliat Care; 2010 Mar; 4(1):16-8. PubMed ID: 20009759
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral delivery of anticancer drugs I: general considerations.
    Mazzaferro S; Bouchemal K; Ponchel G
    Drug Discov Today; 2013 Jan; 18(1-2):25-34. PubMed ID: 22951365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
    Hamad I; Moghimi SM
    Expert Opin Drug Deliv; 2008 Feb; 5(2):205-19. PubMed ID: 18248319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging as a tool for personalized and targeted anticancer therapy.
    McLarty K; Reilly RM
    Clin Pharmacol Ther; 2007 Mar; 81(3):420-4. PubMed ID: 17339871
    [No Abstract]   [Full Text] [Related]  

  • 11. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.
    Da Silva CG; Honeywell RJ; Dekker H; Peters GJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):703-17. PubMed ID: 25633410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and Pharmacokinetics of Anti-Cancer Drugs.
    Desai PB; Sane RS
    Toxicol In Vitro; 2006 Mar; 20(2):133-4. PubMed ID: 16321499
    [No Abstract]   [Full Text] [Related]  

  • 13. Canonical and new generation anticancer drugs also target energy metabolism.
    Rodríguez-Enríquez S; Gallardo-Pérez JC; Hernández-Reséndiz I; Marín-Hernández A; Pacheco-Velázquez SC; López-Ramírez SY; Rumjanek FD; Moreno-Sánchez R
    Arch Toxicol; 2014 Jul; 88(7):1327-50. PubMed ID: 24792321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions in oncology.
    Beijnen JH; Schellens JH
    Lancet Oncol; 2004 Aug; 5(8):489-96. PubMed ID: 15288238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer IGF1R classes take more knocks.
    Guha M
    Nat Rev Drug Discov; 2013 Apr; 12(4):250. PubMed ID: 23535923
    [No Abstract]   [Full Text] [Related]  

  • 16. Liposomal drug formulations in cancer therapy: 15 years along the road.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Drug Discov Today; 2012 Feb; 17(3-4):160-6. PubMed ID: 21983329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel cytotoxic drugs: old challenges, new solutions.
    Ismael GF; Rosa DD; Mano MS; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):81-91. PubMed ID: 17905518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotyping drug disposition in oncology.
    Opdam FL; Gelderblom H; Guchelaar HJ
    Cancer Treat Rev; 2012 Oct; 38(6):715-25. PubMed ID: 22226243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer therapy-induced adverse events: practicing damage control.
    Lacouture ME; Lenihan D; Wu S
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S1-3. PubMed ID: 22409299
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of healthy volunteers drives clinical oncology drug development decision making.
    Iwamoto M; Iannone R; Wagner JA
    Clin Pharmacol Ther; 2012 Nov; 92(5):571-4. PubMed ID: 23010649
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.